TrialAmerican journal of hematology2025

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.

Nichola Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.